Literature DB >> 2733123

Impact of national guidelines for cholesterol risk factor screening. The Framingham Offspring Study.

P W Wilson1, J C Christiansen, K M Anderson, W B Kannel.   

Abstract

Recently published guidelines from the National Cholesterol Education Program were applied to 792 men and 853 women aged 30 to 69 years who participated in Framingham Offspring examination 3 from 1983 to 1987. Using nationally recommended algorithms, cholesterol levels are desirable in 50% of men and women, borderline in 12% of men and 30% of women, and elevated in 35% of men and 19% of women. Assuming that diet reduces low-density lipoprotein cholesterol levels 20%, 10%, or 5%, rates of lipid medication use are projected as 2%, 5%, or 10%, respectively. Applying 6-year estimates of coronary risk derived from the original Framingham cohort to their offspring, the nationally recommended algorithm lacks specificity in women younger than 40 years and in both men and women older than 60 years. This study suggests that effective diet probably will be the cornerstone of current guidelines, and individuals aged 40 to 60 years might benefit most.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2733123

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  10 in total

1.  Patterns and determinants of dyslipidaemia in 'Young' versus 'Not so Young' patients of coronary artery disease: a multicentric, randomised observational study in northern India.

Authors:  Nakul Sinha; Sudeep Kumar; Himanshu Rai; Neha Singh; Aditya Kapoor; Satyendra Tewari; R K Saran; V S Narain; R P S Bharadwaj; R K Bansal; P C Saxena; P R Sinha; P R Gupta; Mukul Mishra; Praveen Jain; C M Pandey; Uttam Singh; S S Agarwal
Journal:  Indian Heart J       Date:  2012 May-Jun

Review 2.  Indications for lipid-lowering drugs.

Authors:  J Davignon
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Lowering the cost of lowering the cholesterol: a formulary policy for lovastatin.

Authors:  F A Lederle; E M Rogers
Journal:  J Gen Intern Med       Date:  1990 Nov-Dec       Impact factor: 5.128

4.  Consequences of current lipid guidelines for the Federal Republic of Germany.

Authors:  L Kohlmeier; H Hoffmeister
Journal:  Klin Wochenschr       Date:  1990-05-04

5.  Atheromatous plaque reflects serum total cholesterol levels: a comparative morphologic study of endarterectomy coronary atherosclerotic plaques removed from patients from the southern part of India and Caucasians from Ottawa, Canada.

Authors:  P J Varghese; S B Arumugam; K M Cherian; V Walley; A Farb; R Virmani
Journal:  Clin Cardiol       Date:  1998-05       Impact factor: 2.882

6.  CORONARY RISK ANALYSIS - A STITCH IN TIME.

Authors:  T P Sreekumar; M K Vyawahare; Cgs Sarma
Journal:  Med J Armed Forces India       Date:  2011-07-21

7.  Reference intervals for plasma L-arginine and the L-arginine:asymmetric dimethylarginine ratio in the Framingham Offspring Cohort.

Authors:  Nicole Lüneburg; Vanessa Xanthakis; Edzard Schwedhelm; Lisa M Sullivan; Renke Maas; Maike Anderssohn; Ulrich Riederer; Nicole L Glazer; Ramachandran S Vasan; Rainer H Böger
Journal:  J Nutr       Date:  2011-10-26       Impact factor: 4.798

8.  Modifying serum lipids to prevent coronary heart disease: do we have a consensus?

Authors:  S A Grover
Journal:  Cardiovasc Drugs Ther       Date:  1993-11       Impact factor: 3.727

9.  Exome sequence association study of levels and longitudinal change of cardiovascular risk factor phenotypes in European Americans and African Americans from the Atherosclerosis Risk in Communities Study.

Authors:  Elena V Feofanova; Elise Lim; Han Chen; MinJae Lee; Ching-Ti Liu; L Adrienne Cupples; Eric Boerwinkle
Journal:  Genet Epidemiol       Date:  2021-06-24       Impact factor: 2.344

10.  Prevalence of common disease-associated variants in Asian Indians.

Authors:  Trevor J Pemberton; Niyati U Mehta; David Witonsky; Anna Di Rienzo; Hooman Allayee; David V Conti; Pragna I Patel
Journal:  BMC Genet       Date:  2008-02-04       Impact factor: 2.797

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.